<p>The drug major Lupin has collaborated with the Mylan for commercialising Enbrel for the treatment of Arthritis. Basically, Embrel is an autoimmune disorder drug. The Mylan will make Lupin&rsquo;s proposed Embrel biosimilar in countries like Europe, Australia, New Zealand, Latin America, Africa and in the markets in Asia. </p><p>Embrel (etanercept) biosimilar is the identical copy of a branded drug, which is currently becoming the one of the largest selling drugs in the world with global sales of approximately $11.6 billion in December month ending 31,2017 as per the IQVIA. </p><p>The first biologic treatment to get approval for the moderate to serve the RA (Rheumatoid Arthritis) in 1998, &amp; it is used for treating 5 long-term inflammatory conditions which are- rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis (JIA). </p><p>The Lupin has also teamed up with the Japanese company Nichi-Iko for selling etanercept in Japan, the product will be launched after receiving the approval from the Japanese drug regulator Pharmaceuticals and Medical Devices Agency (PMDA) </p>rnrn<blockquote><p>"The introduction of biosimilars is an important mechanism to help increase access to more affordable biologics treatments and our industry-leading portfolio of 20 biosimilar products," said Mylan President Rajiv Malik.</p></blockquote><p>Mylan is well-positioned to commercialise our Etanercept biosimilar given their significant expertise and global infrastructure. This partnership enables us to accelerate our Etanercept market plans across multiple regions globally as we continue to advance our pipeline of biosimilar candidates," said Vinita Gupta, CEO, Lupin Limited. </p><p>"The introduction of biosimilars is an important mechanism to help increase access to more affordable biologics treatments and our industry-leading portfolio of 20 biosimilar products," said Mylan President Rajiv Malik. </p>